Bridgefront Capital’s Coherus Oncology CHRS Stock Holding History

Bridgefront Capital’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-26,928	Closed	-$393K	–	635
2021 Q1	$393K	Buy	+26,928	New	+$457K	0.12%	333

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Bridgefront Capital's CHRS Position: Q2 2021 in Review

Bridgefront Capital sold out of Coherus Oncology (CHRS) in Q2 2021, closing a stake of 26,928 shares — an estimated $393K sold.

Bridgefront Capital first reported a position in CHRS in Q1 2021 and held it in 1 quarter. The position peaked at $393K in Q1 2021. 188 funds tracked by Wall St. Rank hold CHRS as of Q2 2021.

Bridgefront Capital reported no remaining Coherus Oncology position as of Q2 2021 after selling out during the quarter.
Bridgefront Capital sold 26,928 Coherus Oncology shares in Q2 2021, an estimated $393K.
Bridgefront Capital first reported a position in Coherus Oncology in Q1 2021 and held it in 1 quarter.
Bridgefront Capital's Coherus Oncology position peaked at $393K in Q1 2021.
188 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2021.

Based on Bridgefront Capital's 13F filing for Q2 2021, filed 12 Aug 2021.